Corren J, Castro M, O’Riordan T, et al. - Given that the LIBERTY ASTHMA QUEST study reports dupilumab-induced decrease in severe asthma exacerbations and improvement in forced expiratory volume in 1 second (FEV₁) in patients treated with it for uncontrolled, moderate-to-severe asthma, with greater effectiveness seen in those with high type 2 inflammatory biomarkers (blood eosinophils and fractional exhaled nitric oxide) at baseline, researchers investigated how dupilumab influenced key asthma results in QUEST patients with/without proof of allergic asthma [total serum immunoglobulin E (IgE) ≥ 30 IU/mL and ≥ 1 perennial aeroallergen-specific IgE ≥ 0.35 kU/L at baseline]. Findings revealed that severe exacerbation rates were reduced, FEV₁ and asthma control were improved, and type 2 inflammatory biomarkers were suppressed following treatment with dupilumab in uncontrolled, moderate-to-severe asthma patients with or without proof of allergic asthma, this emphasizes the key role of interleukin-4 and interleukin-13 in airway inflammation.